Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585387 | 1.00 | MEN1 (0.32) | MEN1KMT2ANAMPTNR1H2TSHR | |
| SCHEMBL18700387 | 0.88 | TSHR (0.33) | MEN1KMT2ANR1H2TSHRALDH1A1 | |
| SCHEMBL585407 | 0.85 | MEN1 (0.33) | MEN1KMT2ANAMPTNR1H2PARP1 | |
| SCHEMBL585406 | 0.85 | MEN1 (0.33) | MEN1KMT2ANAMPTNR1H2PARP1 | |
| SCHEMBL2839477 | 0.81 | NR1H2 (0.41) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL2848749 | 0.81 | NR1H2 (0.41) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL25569891 | 0.81 | PARP1 (0.36) | MEN1KMT2ANR1H2TSHRALDH1A1 | |
| SCHEMBL584255 | 0.81 | NR1H2 (0.41) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL20554159 | 0.80 | MEN1 (0.34) | MEN1KMT2ANAMPTNR1H2TSHR | |
| SCHEMBL20554158 | 0.80 | MEN1 (0.34) | MEN1KMT2ANAMPTNR1H2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102217-B1 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-8039466-B2 | 5-hydroxymethyl-oxazolidin-2-one antibacterials | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| EP-2256120-A1 | Oxazolidinone-quinolone hybrids as antibacterial compounds | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | OGFOD1, ODC1, OXGR1 | MEN1 3048/4885KMT2A 1819/4885NAMPT 3595/4885 |
| US-20100222302-A1 | Novel Antibacterial Compounds | ODC1, AOC1, OGFOD1 | MEN1 3273/4885KMT2A 2428/4885NAMPT 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.